They way it reads it is Cosmo's option to decide. So, #1 the company received the milestone payment for as a result of the "positive" results of the clinical trials. In case you weren't sure if the SNTS press release was just lip service or not, they paid the $3M milestone, so I assume when you pay out that money, it's because they met or surpassed those expectations. #2, Cosmo, the company that is intimately involved in the clinical trials for the drug, said give me the stock instead of the cash. So, that's a pretty good endorsement that the future of this drug is a very good one.
The future stock price of SNTS has a very good chance of increasing dramatically. I still also think that it may not do much until we get more of the news scheduled to be released early next year. So, just hang in there and enjoy the turkey on Thursday!